Social media still stumps clinical trial runners; Report: Biotech's windfall means a payday for CROs;

> CROs and drug companies are still figuring out how to deal with clinical trial participants sharing information via social media. More

> Through IPOs and venture rounds, biotech companies have raised nearly $100 billion over the past 12 months, and CROs are likely in line for a sizable portion of that sum, an analyst tells Outsourcing-Pharma. Story

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.